Anthracycline Derivatives And Their Therapeutic Applications

Patent Status

Patent Pending

Brief Description

Current treatments for cancer often fail due to drug resistance, a significant challenge in oncology. Existing anthracycline derivatives, while effective, can also lead to severe side effects, such as cardiotoxicity, which limits their therapeutic use. This innovative technology, developed by UC Berkeley researchers, addresses these critical problems by creating novel anthracycline derivatives with improved efficacy against chemoresistant cancers and reduced cardiotoxic effects. The new compounds work by overcoming the mechanisms of drug resistance and offering a more tolerable and effective treatment option for patients.

Suggested uses

• Treatment of various types of cancer, including solid tumors and leukemias

• Targeting chemoresistant cancer types that do not respond to conventional therapies

• Use as a standalone chemotherapy agent or in combination with other drugs to enhance therapeutic outcomes

Advantages

• Increased effectiveness against chemoresistant cancer cells

• Reduced cardiotoxic side effects compared to traditional anthracyclines

• Potential for use in a broader range of patients who cannot tolerate existing treatments

• Improved therapeutic index, allowing for more aggressive and successful treatment regimens

Related Materials